- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Antivir Ther. 2015 Sep 17. doi: 10.3851/IMP2992. [Epub ahead of print]
Association of interferon-gamma inducible protein 10 polymorphism with treatment response to pegylated interferon in HBeAg-positive chronic hepatitis B.Limothai U1, Chuaypen N, Khlaiphuengsin A, Posuwan N, Wasitthankasem R, Poovorawan Y, Tangkijvanich P.
Author information
- 1Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
AbstractBACKGROUND: Interferon-gamma inducible protein 10 (IP-10) plays an important role in clinical outcome of chronic hepatitis B (CHB). This study aimed to investigate the association between single nucleotide polymorphisms (SNPs) G-201A of the IP-10 gene and treatment response to pegylated interferon (PEG-IFN) in patients with HBeAg-positive CHB.
METHODS: We retrospectively analyzed data of patients with HBeAg-positive CHB treated with PEG-IFN for 48 weeks. Virological response (VR) was defined as HBeAg clearance and HBV DNA < 2,000 IU/mL at 24 weeks post-treatment. The SNPs G-201A, IFNL3 (rs12979860) and HLA-DPA1 (rs3077) were assessed.
RESULTS: Among 107 patients, VR was achieved in 45 (42.1%) patients. HBsAg clearance and decline (< 100 IU/mL) were observed in 10 (9.3%) and 22 (20.6%) patients, respectively. The distribution of GG, GA and AA genotypes of G-201A was 76.6%, 19.6% and 3.7%, respectively. Patients with GG genotype, compared to those with non-GG genotype, achieved higher VR rate (48.8% vs. 19.2%; P=0.011), decreased HBsAg (25.6% vs. 4.0%, P=0.019), and demonstrated a trend in HBsAg clearance (11.0% vs. 4%, P=0.294). Patients with GG-genotype had more rapid HBsAg decline and higher baseline serum IP-10 levels than those with non-GG genotype (432.2±339.0 vs. 257.3±145.7 pg/mL, P=0.028). SNPs rs12979860 and rs3077 were not associated with VR. Logistic regression analysis suggested that SNP G-201A was an independent predictor of VR (odds ratio 3.81, 95% confidence interval: 1.31-11.12, P=0.014).
CONCLUSIONS: Data from this study demonstrated for the first time that IP-10 polymorphism is independently associated with treatment response to PEG-IFN in patients with HBeAg-positive CHB.
|
|